Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 13,67 € (+111,94 %). La médiane est de 13,67 € (+111,94 %).

Acheter
  11
Conserver
  2
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Evolus beats Q2 2026 revenue forecast and raises full-year target

    Evolus reported Q2 2026 revenue of $84.1m (+21% y/y), beating analysts' estimates and raising the lower end of its full-year revenue guidance to $330m. Adjusted EBITDA was positive at $4.7m for the third consecutive quarter, although EPS of -$0.12 was more negative than expected. Management emphasized portfolio diversification through Evolysse and Profhilo and additional product launches; the stock rose about 5.7% in after-hours trading. » Plus sur de.investing.com


  • Evolus enters exclusive license and distribution agreement for Profhilo in the US

    Evolus has reached an exclusive license and distribution agreement with Swiss pharmaceutical company IBSA for the skin injection Profhilo in the US. Evolus will assume the development activities required for US approval and will market the product after approval; the agreement includes no upfront payments and is based on a transfer-pricing model. The company expects no impact from the agreement on its 2026 guidance or on the revenue and profitability targets for 2028. Profhilo, a superficially acting hyaluronic acid formulation to improve skin quality, has already been used in millions of treatments worldwide since 2015 and complements Evolus' existing portfolio such as Jeuveau and Evolysse. » Plus sur de.investing.com


  • Evolus: shareholders reelect Brady Stewart and Vikram Malik and approve executive compensation

    At Evolus' annual general meeting, Brady Stewart and Vikram Malik were reelected as Class II directors for three years. Shareholders confirmed Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and voted in a non-binding advisory vote to approve the compensation of the named executive officers. Additionally, the company reported mixed Q1 results (EPS missed, revenue slightly above expectations) and plans the European launch of the Estyme dermal filler line. » Plus sur de.investing.com


  • Evolus to launch Estyme dermal filler line in Europe on May 16

    Evolus will introduce the Estyme collection of four injectable hyaluronic acid gels in Europe on May 16, including the globally first commercially available Estyme Sculpt for mid‑face volume restoration. The products are CE‑certified and use Symatese’s Cold‑X technology; FDA approval for Estyme Sculpt is expected later this year. Evolus reported revenue of $301.79 million for the twelve months to Q1 2026 (≈+10%) but remains unprofitable with a negative EPS of -$0.67. » Plus sur de.investing.com


  • Evolus: Jeuveau drives sales, Evolysse fillers show superiority in approval studies

    Evolus presented comprehensive clinical data for its two-pronged approach with Jeuveau and the new Evolysse filler portfolio based on Cold-X™ technology. U.S. approval-relevant studies show that Evolysse Form and Smooth were not only non-inferior but statistically superior to Restylane-L at six months; Evolysse Sculpt achieved non-inferiority and high responder rates for volume augmentation. Jeuveau delivered solid Phase III results versus Botox and data on a higher‑dose formulation with longer duration; safety profiles remained favorable. On the financial side, Evolus reported Q1 revenue of $73.1 million, reaffirmed full-year guidance and is targeting continued double-digit revenue growth and positive adjusted EBITDA. » Plus sur de.investing.com

En 2022, Evolus a déjà versé 0,26 € de dividendes. Le dernier versement a eu lieu en mars 2022.

Données financières de l'entreprise

Au dernier trimestre, Evolus a réalisé un chiffre d'affaires de 68,82 M € et un bénéfice net de -11,05 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 68,82 M 17,10 %
Bénéfice brut 44,75 M 14,56 %
Bénéfice net -11,05 M 17,60 %
EBITDA -5,66 M 27,81 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
426,41 M €
Nombre d'actions
66,19 M
Plus haut/bas sur 52 semaines
8,48 € - 3,52 €
Dividendes Non
Bêta
1,34
Ratio P/E
-15,11
Ratio PEG
-0,20
Ratio P/B
-12,36
Ratio P/S
1,44

Profil de l'entreprise

Evolus, Inc., une entreprise de beauté axée sur la performance, propose des produits d'esthétique médicale destinés aux médecins et à leurs patients aux États-Unis. Elle commercialise Jeuveau, une formulation propriétaire de toxine botulique de type A purifiée à 900 kilodaltons, indiquée pour l'amélioration temporaire de l'apparence des rides glabellaires modérées à sévères chez l'adulte. La société a été constituée en 2012 et a son siège social à Newport Beach, en Californie.

Nom
Evolus
PDG
David Moatazedi
Siège social Newport Beach, ca
États-Unis
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
08/02/2018
Employés 353

Symboles boursiers

Bourse Symbole
NASDAQ
EOLS
London Stock Exchange
0K16.L
Frankfurt
EVL.F
Düsseldorf
EVL.DU
London
0K16.L
München
EVL.MU
🍪

Parqet  utilise des cookies. En savoir plus